Maintained Clinical Remission in Ankylosing Spondylitis Patients Switched from Reference Infliximab to Its Biosimilar: An 18-Month Comparative Open-Label Study

Background: Switching from reference infliximab (RI) to biosimilar infliximab (BI) had no detrimental effects on efficacy and safety. However, long-term follow-up data is missing. Objective: To evaluate patients with Ankylosing Spondylitis (AS) in clinical remission who were switching from RI to BI,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaltsonoudis, Evripidis, Pelechas, Eleftherios, Voulgari, Paraskevi V., Drosos, Alexandros A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679061/
https://www.ncbi.nlm.nih.gov/pubmed/31269678
http://dx.doi.org/10.3390/jcm8070956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6679061/
https://www.ncbi.nlm.nih.gov/pubmed/31269678
http://dx.doi.org/10.3390/jcm8070956

Ejemplares similares